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See Articles, pages 490–499 and 530–537Lenin could have hardly imagined that his words describing the
Bolshevik revolution almost 100 years ago could be applied to
the breathtaking approvals in HCV therapies in the past few
weeks. Yet, if one deﬁnes ‘revolution’ (from the Latin revolutio,
‘‘a turnaround’’) as ‘‘a signiﬁcant change that usually occurs in a
short period of time’’, there is little doubt that we are experiencing
a revolutionary epoch in hepatology, and practitioners would be
wise to mark this watershed in their collective memories. After
over a decade of only modest improvements upon standard
interferon-based therapies, the recent FDA approvals and
anticipated EMA approvals of sofosbuvir and simeprevir – albeit
currently in combinationwith interferon and ribavirin – represent
the leading edge of what will be a new era of interferon-free
regimens that promise to cure more than 90% of genotype 1
patients, using regimens that are well tolerated and will rescue
many patients in whom interferon is either unsafe or not
tolerable. These advances have generated excitement among the
lay and scientiﬁc press [1,2], patients, providers, pharmaceutical
and biotech companies, and investors.
A study by Younossi et al. in this month’s issue of the Journal
estimates the predicted economic and clinical windfall of this
revolution using Markov modeling. In this study, the authors
compared the calculated incremental cost-effectiveness ratio
(ICER) between patients treated with standard interferon based
triple therapy (interferon, ribavirin, and either telaprevir or boce-
previr) with those treated with all oral regimens for 12 weeks,
based on published distributions of ﬁbrosis stage, current costs
of therapy and health care, and drug efﬁcacies. They also distin-
guished between predictions based on whether patients were
ﬁrst screened with transient elastography (e.g., FibroScan) as
the staging method in order to limit therapy to only those with
more advanced ﬁbrosis; estimates that included the cost of liver
biopsy were restricted to the sensitivity analysis. Of note, the
study was performed before FibroScan was approved in the
US, and as of this writing the cost is still not determined, soJournal of Hepatology 20
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authors also made the estimate that the average total treatment
cost of oral therapy was equal to the average total treatment cost
of triple therapy, since the actual costs were not known at the
time of their study.
The model’s ﬁndings clearly favor the use of all oral regimens
in all patients with HCV over the use of triple therapy, and also
predict that treating all patients would be cost-effective com-
pared to using staging-guided therapies. The all oral regimen
without staging would yield an ICER of $15,709 quality-adjusted
life years (QALY), well below the threshold of $50,000 often used
to provide justiﬁcation for new therapies. Moreover, neither a
signiﬁcant reduction in the cost of boceprevir/telaprevir, nor in
the cost of staging would have any impact on the predicted
advantage to using all oral therapy without staging guidance.
As the authors point out, the ﬁndings take on added signiﬁ-
cance with an expected increase in the detection of HCV in the
United States following the endorsement of recommendations
by the CDC and US Preventive Services Task Force to conduct
widespread one-time HCV screening in patients between 45
and 65 years old. Modeling predictions like this study’s
supporting the use of a ‘test and treat’ strategy could greatly
simplify the linkage to care following HCV diagnosis that is so
vital for effective disease eradication in at-risk populations [3].
Of course, the analysis by Younossi et al. relies on major
assumptions regarding drug efﬁcacy, costs, and adverse events,
which could well be higher in the real world than that seen in
clinical trials. This was the experience in the use of triple therapy
that includes boceprevir or telaprevir, where the incidence of
adverse events in clinical practice after the drugs were approved
was much higher, and the events more severe than what was
experienced in pre-approval studies [3,4]. This unexpected prob-
lem arose in part because after the drugs were approved they
were ﬁrst given to those with the most urgent need for cure
(i.e., cirrhotics), even though these same patients had the least
capacity to tolerate adverse events.
Moreover, treatment with all oral regimens may not be so
straightforward in every patient, particularly those who previ-
ously failed interferon-based regimens or with HCV genotype
1a. For example, in the article by Lok et al., also in this issue of
the Journal, the results of a phase II trial that included two exper-
imental direct-acting antivirals (daclatasvir and asunaprevir)
underscores the more labor-intensive and customized treatments14 vol. 60 j 471–472
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that will be required in prior null responders, especially the need
to distinguish between genotypes 1a and 1b. In the Lok et al.
study, which was a randomized open label trial testing a series
of combinations with or without interferon, 99% of the patients
had the non-CC IL-28 genotype associated with interferon
resistance, which explains their prior non-responses. In these
difﬁcult-to-treat patients, those with genotype 1a required inter-
feron-based combinations to achieve an SVR. Thus, prior non-
response was a tipoff to the need for more detailed diagnosis
(e.g., viral and possible IL-28 genotyping) and customized ther-
apy, yet as we screen and uncover more untreated HCV, some will
also have genotype 1a and a non-CC IL-28 genotype and will pos-
sibly fail an all oral combination. Indeed, the simeprevir drug
label will indicate that in genotype 1a patients resistance testing
should be performed for the ‘Q80K’ mutation. If present, then
‘‘other therapies should be considered.’’ Thus, should our initial
algorithm include both HCV and IL-28 genotyping, or should
we wait until such patients fail initial therapy and then consider
retreatment with an interferon-based regimen? If so, will viral
resistance from initial therapy limit efforts to retreat? These are
the kinds of nuanced questions, which color the interpretation
of the Markov modeling used by Younossi, although they do
not undermine it.
As we enter this momentous transition towards an
‘interferon-free’ world, it is also worth looking back to ask which
advances were absolutely critical to bringing us to this juncture. I
would contend that three seminal discoveries were essential: (1)
The discovery of the HCV agent by Houghton, Choo, Kuo, Bradley
and colleagues [5], a Nobel-worthy achievement both because of
its public health impact and for the brilliant new methodology
they formulated to clone the virus; (2) The development of cell
based culture systems that supported HCV, ﬁrst using the repli-
con [6] and then later the infectious JFH1 virus systems [7,8],
which enabled high throughput drug screening and the discovery
of obligate cellular receptors for HCV [9]; (3) The characterization
of HCV protein structures, which greatly facilitated the design of
direct-acting antiviral drugs.
Does this mean that all the other investments in HCV research
were irrelevant? Not at all. The discovery of HCV could not have
happened without years of clinical characterization of non-A
non-B hepatitis cases and studies in non-human primates, among
others. Similarly, revealing how HCV evades immune clearance
and how it drives intracellular innate immune signaling have
already borne fruit in helping us understand the pathogenesis
of other viral infections, and will also be vital in developing a
prophylactic HCV vaccine.
Another important implication of these three seminal discov-
eries is that they reﬂect a healthy synergy between the academic
and commercial research spaces. Both the discovery of the virus
and the development of new drugs took place in the biotech/472 Journal of Hepatology 201pharmaceutical sphere, yet they could not have happened with-
out equally important discoveries in academia, including the clin-
ical studies before and after the discovery of the virus, and the
characterization of cell culture systems to enable drug screening.
In fact, one could argue that the HCV success story represents an
ideal consequence of a healthy, interdependent ecosystem
between academic and commercial research.
This brings us back to the words of Lenin and the exciting
times we live in as investigators or clinicians devoted to liver
disease. We can only hope that decades do not pass again before
witnessing another revolution in our specialty, but just in case
let’s enjoy this rare view while we can.Conﬂict of interest
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